Ok_老虎社区_美港股上老虎

Jeffchew
2021-11-26

Alibaba-Backed Creative Biosciences Weighing Hong Kong IPO

Creative Biosciences (Guangzhou) Co., a developer of DNA testing kits for colorectal cancer, is cons

Alibaba-Backed Creative Biosciences Weighing Hong Kong IPO

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":877238523,"tweetId":"877238523","gmtCreate":1637933944199,"gmtModify":1637933944199,"author":{"id":4092541343605400,"authorId":4092541343605400,"authorIdStr":"4092541343605400","name":"Jeffchew","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":4,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Ok</p></body></html>","htmlText":"<html><head></head><body><p>Ok</p></body></html>","text":"Ok","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/877238523","repostId":1137032995,"repostType":4,"repost":{"id":"1137032995","pubTimestamp":1637927757,"share":"https://www.laohu8.com/m/news/1137032995?lang=&edition=full","pubTime":"2021-11-26 19:55","market":"hk","language":"en","title":"Alibaba-Backed Creative Biosciences Weighing Hong Kong IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1137032995","media":"Bloomberg","summary":"Creative Biosciences (Guangzhou) Co., a developer of DNA testing kits for colorectal cancer, is cons","content":"<p>Creative Biosciences (Guangzhou) Co., a developer of DNA testing kits for colorectal cancer, is considering an initial public offering in Hong Kong as soon as next year, people with knowledge of the matter said.</p>\n<p>The Chinese firm, backed by Alibaba Group Holding Ltd., has been in discussions with potential advisers about a listing, said the people, who asked not to be identified as the information is private. The prospective IPO could raise about $200 million, the people said.</p>\n<p>Deliberations are at an early stage, and details such as fundraising size and timing could change, the people said. Representatives for CreativeBio didn’t immediately respond to a request for comment.</p>\n<p>Founded in 2015, Guangzhou-based CreativeBio focuses on research and development of fecal DNA testing kits for colorectal cancer and its related automation equipment, as well as production, sales, and linked services, according to its website.</p>\n<p>Last month, the company announced the completion of a 560 million yuan ($88 million) series D funding round, led by Alibaba. Other investors that participated include Huaxing Growth Capital under China Renaissance Holdings Ltd., CoStone Capital, ABC International and Henglu Asset, according to a press release at the time.</p>\n<p>The biotech firm also counts CDH Investments, IDG Capital and Sinopharm Capital among others as backers, its website shows.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alibaba-Backed Creative Biosciences Weighing Hong Kong IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlibaba-Backed Creative Biosciences Weighing Hong Kong IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-26 19:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-26/alibaba-backed-creative-biosciences-said-to-weigh-hong-kong-ipo><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Creative Biosciences (Guangzhou) Co., a developer of DNA testing kits for colorectal cancer, is considering an initial public offering in Hong Kong as soon as next year, people with knowledge of the ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-26/alibaba-backed-creative-biosciences-said-to-weigh-hong-kong-ipo\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"HSI":"恒生指数"},"source_url":"https://www.bloomberg.com/news/articles/2021-11-26/alibaba-backed-creative-biosciences-said-to-weigh-hong-kong-ipo","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137032995","content_text":"Creative Biosciences (Guangzhou) Co., a developer of DNA testing kits for colorectal cancer, is considering an initial public offering in Hong Kong as soon as next year, people with knowledge of the matter said.\nThe Chinese firm, backed by Alibaba Group Holding Ltd., has been in discussions with potential advisers about a listing, said the people, who asked not to be identified as the information is private. The prospective IPO could raise about $200 million, the people said.\nDeliberations are at an early stage, and details such as fundraising size and timing could change, the people said. Representatives for CreativeBio didn’t immediately respond to a request for comment.\nFounded in 2015, Guangzhou-based CreativeBio focuses on research and development of fecal DNA testing kits for colorectal cancer and its related automation equipment, as well as production, sales, and linked services, according to its website.\nLast month, the company announced the completion of a 560 million yuan ($88 million) series D funding round, led by Alibaba. Other investors that participated include Huaxing Growth Capital under China Renaissance Holdings Ltd., CoStone Capital, ABC International and Henglu Asset, according to a press release at the time.\nThe biotech firm also counts CDH Investments, IDG Capital and Sinopharm Capital among others as backers, its website shows.","news_type":1},"isVote":1,"tweetType":1,"viewCount":417,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}